Sal Patel, JD: Settlements That End Patent Litigation

Sal Patel, JD, partner at Schiff Hardin, LLP, explains why he expects to see more settlements between drug manufacturers in the future.

Transcript:

Recently, a biosimilar developer settled with AbbVie to end patent litigation over Humira. Do you think we’ll see more settlements like this in the future?

Absolutely. I think just as we see in Hatch-Waxman cases, I think there will be creative settlements that will be employed to end the uncertainty and the cost of the [Biologics Price Competition and Innovation Act, BPCIA] litigation, which I anticipate is going to be much higher than what we see with Hatch-Waxman litigation.

Related Videos
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
andre harvin
Andre Harvin, PharmD
Christine Baeder
Christine Baeder Smiling
Michael Kleinrock
Ian Henshaw
Ian Henshaw
Ryan Haumschild, PharmD
John Gabrielson
Related Content
© 2023 MJH Life Sciences

All rights reserved.